This is a routine administrative amendment to comply with SEC reporting requirements. There is no new financial information or material change in the company's operations, financial condition, or executive compensation. Traders should note that the lack of a proxy statement may limit insight into future governance or compensation plans, but the core financials and operations remain unchanged from the original filing.
Price Chart
Executive Summary
Syra Health Corp filed an amended 10-K/A solely to include Part III information (directors, executive compensation, related party transactions, and auditor fees) that was previously omitted because the company will not file a definitive proxy statement within 120 days of its fiscal year-end. No financial statements or other disclosures were amended. The filing includes updated Sarbanes-Oxley Section 302 certifications from the CEO and CFO.
Key Facts
- Amendment is solely to include required Part III disclosures (Items 10-14) that were omitted from the original 10-K.
- No financial statements were amended or restated.
- The company will not file a definitive proxy statement within 120 days of its fiscal year-end, necessitating this amendment.
- Updated Section 302 certifications from CEO Gregory Alexander and CFO Priya Prasad are included.
- No other changes were made to the original 10-K filing.
Financial Impact
No financial impact. This amendment does not correct any financial statements or material errors.
Risk Factors
- The need for an amendment to include Part III information could signal internal process or governance issues, although it is not uncommon for smaller reporting companies.
- The absence of a proxy statement may limit transparency for investors regarding future shareholder votes or compensation proposals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001493152-26-019010 |
| Exhibit: ex31-2.htm | 0001493152-26-019010 |
| Exhibit: ex31-1.htm | 0001493152-26-019010 |
| Document: 0001493152-26-019010-index-headers.html | 0001493152-26-019010 |
| Document: 0001493152-26-019010-index.html | 0001493152-26-019010 |
| Document: 0001493152-26-019010.txt | 0001493152-26-019010 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $0.8500 $0.8300 | ▼ −2.35% | ▼ −1.20% | $0.8600 (+1.18%) |
Sep 14, 2026 6w ago | S-1 | $0.9400 $0.9600 | ▲ +2.13% | ▲ +1.31% | $0.8600 (−8.51%) |
Aug 11, 2026 11w ago | 8-K | $0.6650 $0.7800 | ▲ +17.29% | ▲ +17.70% | $0.8600 (+29.32%) |
Jun 1, 2026 21w ago | DEFA14A | $0.5100 $0.4900 | ▼ −3.92% | ▼ −0.96% | $0.8600 (+68.63%) |
May 7, 2026 24w ago | 8-K | $0.5000 $0.4390 | ▼ −12.20% | ▼ −13.70% | $0.8600 (+72.00%) |
Apr 24, 2026 26w ago | 10-K/A | $0.4180 $0.4100 | ▼ −1.91% | ▼ −2.31% | $0.8600 (+105.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers